organ transplantation

Summary

Summary: Transference of an organ between individuals of the same species or between individuals of different species.

Top Publications

  1. ncbi Transmission of lymphocytic choriomeningitis virus by organ transplantation
    Staci A Fischer
    Rhode Island Hospital and Brown Medical School, Providence, USA
    N Engl J Med 354:2235-49. 2006
  2. ncbi International consensus guidelines on the management of cytomegalovirus in solid organ transplantation
    Camille N Kotton
    Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Boston, MA 02114, USA
    Transplantation 89:779-95. 2010
  3. ncbi Infection in solid-organ transplant recipients
    Jay A Fishman
    Transplant Infectious Disease and Compromised Host Program, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA
    N Engl J Med 357:2601-14. 2007
  4. pmc Spectrum of cancer risk among US solid organ transplant recipients
    Eric A Engels
    National Cancer Institute, 6120 Executive Blvd, EPS 7076, Rockville, MD 20892, USA
    JAMA 306:1891-901. 2011
  5. ncbi Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN')
    K Solez
    University of Alberta, Edmonton, Alberta, Canada
    Am J Transplant 7:518-26. 2007
  6. ncbi Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations
    Deepa Jagadeesh
    The University of Massachusetts Medical School, Worcester, MA, USA
    Curr Treat Options Oncol 13:122-36. 2012
  7. ncbi Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation
    Christine E Staatz
    School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia
    Clin Pharmacokinet 43:623-53. 2004
  8. ncbi Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation
    Mary Amanda Dew
    1 Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Transplantation 83:858-73. 2007
  9. ncbi Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial
    Tanzina Haque
    Clinical and Molecular Virology Laboratory, University of Edinburgh, Edinburgh, United Kingdom
    Blood 110:1123-31. 2007
  10. ncbi Sirolimus for calcineurin inhibitors in organ transplantation: contra
    Paolo Cravedi
    Mario Negri Institute for Pharmacological Research, Bergamo Unit of Nephrology, Azienda Ospedaliera Ospedali Riuniti, Bergamo, Italy
    Kidney Int 78:1068-74. 2010

Detail Information

Publications296 found, 100 shown here

  1. ncbi Transmission of lymphocytic choriomeningitis virus by organ transplantation
    Staci A Fischer
    Rhode Island Hospital and Brown Medical School, Providence, USA
    N Engl J Med 354:2235-49. 2006
    ..Each cluster was investigated because diagnostic evaluations were unrevealing, and in each a common donor was recognized...
  2. ncbi International consensus guidelines on the management of cytomegalovirus in solid organ transplantation
    Camille N Kotton
    Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Boston, MA 02114, USA
    Transplantation 89:779-95. 2010
    Cytomegalovirus (CMV) remains one of the most common infections after solid organ transplantation, resulting in significant morbidity, graft loss, and occasional mortality. Management of CMV varies considerably among transplant centers...
  3. ncbi Infection in solid-organ transplant recipients
    Jay A Fishman
    Transplant Infectious Disease and Compromised Host Program, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA
    N Engl J Med 357:2601-14. 2007
  4. pmc Spectrum of cancer risk among US solid organ transplant recipients
    Eric A Engels
    National Cancer Institute, 6120 Executive Blvd, EPS 7076, Rockville, MD 20892, USA
    JAMA 306:1891-901. 2011
    ..Because most prior research has concerned kidney recipients, large studies that include recipients of differing organs can inform cancer etiology...
  5. ncbi Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN')
    K Solez
    University of Alberta, Edmonton, Alberta, Canada
    Am J Transplant 7:518-26. 2007
    ..Participation of B cells in allograft rejection and genomics markers of rejection were also major subjects addressed by the conference...
  6. ncbi Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations
    Deepa Jagadeesh
    The University of Massachusetts Medical School, Worcester, MA, USA
    Curr Treat Options Oncol 13:122-36. 2012
    ..Finally, novel therapeutic strategies, especially adoptive immunotherapy, should continued to be explored...
  7. ncbi Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation
    Christine E Staatz
    School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia
    Clin Pharmacokinet 43:623-53. 2004
    ..Little is known about the magnitude of the pharmacodynamic variability of tacrolimus...
  8. ncbi Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation
    Mary Amanda Dew
    1 Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Transplantation 83:858-73. 2007
    Despite the impact of medical regimen nonadherence on health outcomes after organ transplantation, there is mixed and conflicting evidence regarding the prevalence and predictors of posttransplant nonadherence...
  9. ncbi Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial
    Tanzina Haque
    Clinical and Molecular Virology Laboratory, University of Edinburgh, Edinburgh, United Kingdom
    Blood 110:1123-31. 2007
    ..Our results show that allogeneic CTLs are a safe and rapid therapy for PTLD, bypassing the need to grow CTLs for individual patients. The response rate in this poor prognosis patient group is encouraging...
  10. ncbi Sirolimus for calcineurin inhibitors in organ transplantation: contra
    Paolo Cravedi
    Mario Negri Institute for Pharmacological Research, Bergamo Unit of Nephrology, Azienda Ospedaliera Ospedali Riuniti, Bergamo, Italy
    Kidney Int 78:1068-74. 2010
    ....
  11. ncbi Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report
    Jutta K Preiksaitis
    Provincial Laboratory for Public Health Microbiology, University of Alberta, Edmonton, Alberta, Canada
    Am J Transplant 5:218-27. 2005
    ..of this group were to determine the current burden of CMV-associated disease in the setting of solid organ transplantation in Canada, make recommendations regarding optimal strategies for the diagnosis, treatment and prevention ..
  12. ncbi Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success
    S A Lodhi
    Division of Nephrology, Hypertension and Renal Transplantation, Department of Medicine, University of Florida, FL, USA
    Am J Transplant 11:1226-35. 2011
    ..With first-year survival and attrition rates almost at a pinnacle, further progress in long-term survival will come from targeting endpoints beyond first-year rejection and survival rates...
  13. ncbi Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference
    Pierre Wallemacq
    Department of Clinical Chemistry, Laboratory of Toxicology and Therapeutic Drug Monitoring, Universite Catholique de Louvain, University Hospital St Luc, 10 Hippocrate Avenue, Brussels, Belgium
    Ther Drug Monit 31:139-52. 2009
    ....
  14. pmc Cancer risk following organ transplantation: a nationwide cohort study in Sweden
    J Adami
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Br J Cancer 89:1221-7. 2003
    A substantial excess risk of lymphomas and nonmelanoma skin cancer has been demonstrated following organ transplantation. Large sample size and long follow-up time may, however, allow more accurate risk estimates and detailed ..
  15. ncbi Transmission of West Nile virus from an organ donor to four transplant recipients
    Martha Iwamoto
    Epidemic Intelligence Service, Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta 30333, USA
    N Engl J Med 348:2196-203. 2003
    In August 2002, fever and mental-status changes developed in recipients of organs from a common donor. Transmission of West Nile virus through organ transplantation was suspected.
  16. ncbi Noninvasive ventilation for treatment of acute respiratory failure in patients undergoing solid organ transplantation: a randomized trial
    M Antonelli
    Istituto di Anestesiologia e Rianimazione, Università Cattolica del Sacro Cuore Rome, Italy
    JAMA 283:235-41. 2000
    ..Noninvasive ventilation (NIV) has been associated with lower rates of endotracheal intubation in populations of patients with acute respiratory failure...
  17. ncbi Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation
    V C Emery
    Department of Virology, Royal Free and University College Medical School, London, UK
    Lancet 355:2032-6. 2000
    ..Peak CMV load in the blood correlates with CMV disease but frequently occurs too late to provide prognostic information...
  18. ncbi Impact of HLA matching and HLA antibodies in organ transplantation: a collaborative transplant study view
    Caner Süsal
    Department of Transplantation Immunology, Institute of Immunology, University of Heidelberg, Heidelberg, Germany
    Methods Mol Biol 882:267-77. 2012
    ..and originated from the need to gain further insight into the complex problems and risks involved in human organ transplantation. Currently, more than 400 transplant centers in 45 countries are contributing to this voluntary ..
  19. ncbi Immunosuppression affects CD4+ mRNA expression and induces Th2 dominance in the microenvironment of cutaneous squamous cell carcinoma in organ transplant recipients
    Maria Kosmidis
    Department of Dermatology, University Hospital Zurich, Gloriastrasse, Zurich, Switzerland
    J Immunother 33:538-46. 2010
    ....
  20. ncbi Psychological assessment and care of organ transplant patients
    Mary Ellen Olbrisch
    Department of Psychiatry, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298 0268, USA
    J Consult Clin Psychol 70:771-83. 2002
    ..Finally, new developments in transplant and suggestions for future psychological research in organ transplant are presented...
  21. ncbi Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation
    Qisi Wu
    The Second Affiliated Hospital, Chongqing Medical University, Chongqing, PR China
    Eur Neurol 64:169-77. 2010
    ..Therefore, in this review, the focus is on the current understanding of clinical recognition, pathogenesis, neuroimaging and management of TAC-associated PRES after solid organ transplantation.
  22. ncbi B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders
    Riccardo Dolcetti
    Immunovirology and Biotherapy Unit, Department of Pre Clinical and Epidemiological Research C R O I R C C S, National Cancer Institute, 33081 Aviano PN, Italy
    Autoimmun Rev 7:96-101. 2007
    ....
  23. ncbi IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment
    Carl Hinrichs
    Department of Nephrology and Intensive Care, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
    Transpl Int 24:892-903. 2011
    ..Although the specificity of these cells is unclear, their increase might correlate with the impaired tumor-specific cytotoxic-T-lymphocyte (CTL)-response in PTLD...
  24. ncbi Does rituximab increase the incidence of infectious complications? A narrative review
    Theodoros Kelesidis
    Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, CHS 37 121, Los Angeles, CA 90095, USA
    Int J Infect Dis 15:e2-16. 2011
    ..However, clinical experience regarding the association of rituximab with different types of infection is lacking and this association has not been established in patients with rheumatoid arthritis...
  25. ncbi Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study
    Sylvain Choquet
    Hematology Unit, CHU La Pitié Salpêtrière Hospital, 47 bd de l Hopital, 75651 Paris Cedex 14, France
    Blood 107:3053-7. 2006
    ..PTLD, was designed to evaluate the efficacy and safety of rituximab in patients with B-PTLD after solid organ transplantation (SOT). Forty-six patients were included and 43 patients were analyzed...
  26. ncbi BK polyomavirus in solid organ transplantation
    H H Hirsch
    Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    Am J Transplant 13:179-88. 2013
    ..Retransplantation after PyVAN is largely successful, but requires close monitoring for recurrent BKV viremia...
  27. ncbi Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation
    Stanley C Jordan
    Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Expert Rev Clin Immunol 7:341-8. 2011
    ..Here, we discuss these important advancements and their relevance to transplant medicine...
  28. ncbi Treatment of PTLD with rituximab or chemotherapy
    R L Elstrom
    Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, USA
    Am J Transplant 6:569-76. 2006
    ..PTLD patients requiring therapy beyond RI should be considered for rituximab, especially with EBV-positive disease. Chemotherapy should be reserved for patients who fail rituximab, have EBV-negative tumors or need a rapid response...
  29. ncbi Imaging of posttransplantation lymphoproliferative disorder after solid organ transplantation
    Amir A Borhani
    Department of Diagnostic Imaging, University of Pittsburgh Medical Center Presbyterian Campus, 200 Lothrop St, CHP MT Suite 3850, Pittsburgh, PA 15213, USA
    Radiographics 29:981-1000; discussion 1000-2. 2009
    ..Knowledge of the distribution and radiologic features of PTLD allows the radiologist to play a pivotal role in making an early diagnosis and in guiding biopsy...
  30. ncbi Increased plasma interleukin-6 in donors is associated with lower recipient hospital-free survival after cadaveric organ transplantation
    Raghavan Murugan
    CRISMA Laboratory, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA
    Crit Care Med 36:1810-6. 2008
    ..the inflammatory response characteristics in brain-dead organ donors and examine associations with organ transplantation and recipient survival...
  31. pmc MicroRNAs as biomarkers in solid organ transplantation
    V R Mas
    Translational Genomics Transplant Laboratory, Transplant Division, Department of Surgery, University of Virginia, Charlottesville, USA
    Am J Transplant 13:11-9. 2013
    Important progress has been made in improving short-term outcomes in solid organ transplantation. However, long-term outcomes have not improved during the last decades...
  32. ncbi Tolerogenic dendritic cells: applications for solid organ transplantation
    Gaëlle Beriou
    INSERM UMR643, CHU Hotel Dieu, 30 Boulevard Jean Monnet, Nantes, France
    Curr Opin Organ Transplant 17:42-7. 2012
    We discuss the use of tolerogenic dendritic cells (TolDCs) as a therapeutic tool in solid organ transplantation, with particular emphasis on recent experimental and preclinical data supporting the clinical translation of TolDC therapy.
  33. ncbi Mesenchymal stem cells: application for solid-organ transplantation
    Marieke Roemeling-van Rhijn
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Curr Opin Organ Transplant 17:55-62. 2012
    ..These properties make MSCs interesting for use as a cell therapeutic agent in solid-organ transplantation (SOT)...
  34. ncbi Nonadherent behaviors after solid organ transplantation
    G Germani
    Gastroenterology Department of Surgical and Gastroenterological Sciences, Padua University Hospital, Padova, Italy
    Transplant Proc 43:318-23. 2011
    ..to prevent medical complications that negatively influence graft function and patient survival after organ transplantation. The aim of this study was to assess, among patients who underwent solid organ transplantation, ..
  35. ncbi New developments in the management of cytomegalovirus infection after solid organ transplantation
    Albert J Eid
    Division of Infectious Diseases, University of Kansas Medical Center, Kansas City, Kansas, USA
    Drugs 70:965-81. 2010
    ..Prevention of CMV infection and disease is therefore key in ensuring the successful outcome of solid organ transplantation (SOT)...
  36. ncbi Ischemic preconditioning in solid organ transplantation: from experimental to clinics
    Joan Torras Ambros
    Department of Medicine, Laboratory of Nephrology and Nephrology Service, IDIBELL Hospital Universitari Bellvitge, University of Barcelona, Barcelona, Spain
    Transpl Int 20:219-29. 2007
    ..IP is ubiquitous but more research is required to fully translate these findings to the clinical arena...
  37. ncbi Community preferences for the allocation of solid organs for transplantation: a systematic review
    Allison Tong
    Centre for Kidney Research, The Children s Hospital at Westmead, Sydney, NSW 2145, Australia
    Transplantation 89:796-805. 2010
    ..This systematic review aimed to ascertain community preferences for organ allocation and the principles underpinning these preferences...
  38. ncbi Composite tissue allograft extends a helping hand to transplant immunologists
    O Thaunat
    Institut National de la Santé et de la Recherche Médicale U681, Institut Biomedical des Cordeliers, Universite Pierre et Marie Curie Paris VI, Paris, France
    Am J Transplant 6:2238-42. 2006
    ..In this sense, composite tissue allografts extend a helping hand to transplant immunologists...
  39. ncbi Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT)
    Martin J Hoogduijn
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Transplantation 90:124-6. 2010
    There is evolving interest in the use of mesenchymal stem cells (MSC) in solid organ transplantation. Pre-clinical transplantation models show efficacy of MSC in prolonging graft survival and a number of clinical studies are planned or ..
  40. ncbi Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation
    Dirk R J Kuypers
    Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium
    Clin J Am Soc Nephrol 5:341-58. 2010
    With the increasing use of mycophenolic acid (MPA) in solid organ transplantation, the need for more accurate drug dosing has become evident...
  41. ncbi Immunosuppressive drugs and the risk of cancer after organ transplantation
    Jacques Dantal
    N Engl J Med 352:1371-3. 2005
  42. ncbi Dendritic cells as a tool to induce transplantation tolerance: obstacles and opportunities
    Cees van Kooten
    Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands
    Transplantation 91:2-7. 2011
    ..We discuss some obstacles and possible solutions including alternative strategies for the use of negative vaccination in the context of organ transplantation.
  43. pmc Tolerogenic dendritic cells and their role in transplantation
    Mohamed Ezzelarab
    Thomas E Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, 200 Lothrop Street, BST W1540, Pittsburgh, PA 15261, USA
    Semin Immunol 23:252-63. 2011
    ..Evaluation of technical and therapeutic logistic issues is an important next step prior to the application of tolerogenic DC in clinical organ transplantation.
  44. ncbi Green fluorescent protein-transgenic rat: a tool for organ transplantation research
    Y Hakamata
    Center for Molecular Medicine, Jichi Medical School, Kawachi, Tochigi, Japan
    Biochem Biophys Res Commun 286:779-85. 2001
    ..purpose of this study is to evaluate green fluorescent protein (GFP) transgenic rats for use as a tool for organ transplantation research. The GFP gene construct was designed to express ubiquitously...
  45. ncbi Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program
    J Morgan
    Mycotic Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333, USA
    Med Mycol 43:S49-58. 2005
    ..Our CI figures are lower compared to those of previous reports. The reasons for this are unclear, but may be related to changes in transplantation practices, diagnostic methods, and supportive care...
  46. ncbi Costimulatory pathways in transplantation: challenges and new developments
    Xian C Li
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Immunol Rev 229:271-93. 2009
    ....
  47. ncbi Review article: Luminex technology for HLA antibody detection in organ transplantation
    Brian D Tait
    Victorian Transplantation and Immunogenetic Service, Australian Red Cross Blood Service, Parkville, Victoria, Australia
    Nephrology (Carlton) 14:247-54. 2009
    ..leucocyte antigen (HLA) antibodies, not only in pre-transplant renal patients, but also in other forms of organ transplantation. Recently, solid phase assays have been developed and introduced for this purpose, and in particular the ..
  48. ncbi Skin cancers after organ transplantation
    Sylvie Euvrard
    Department of Dermatology, Edouard Herriot Hospital, Lyons, France
    N Engl J Med 348:1681-91. 2003
  49. ncbi Immunosuppression by retroviruses: implications for xenotransplantation
    J Denner
    Paul Ehrlich Institut, Langen, Germany
    Ann N Y Acad Sci 862:75-86. 1998
    ....
  50. ncbi New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation
    Hylke de Jonge
    Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium
    Ther Drug Monit 31:416-35. 2009
    ..TDM) of immunosuppressive drugs has been an integral part of routine clinical practice in solid organ transplantation for many years, ongoing research in the field of immunosuppressive drug metabolism, pharmacokinetics, ..
  51. ncbi Effects of different sensitization events on HLA alloimmunization in solid organ transplantation patients
    J Hyun
    Department of Laboratory Medicine, Hallym University College of Medicine, Seoul, Korea
    Transplant Proc 44:222-5. 2012
    HLA alloimmunization is caused by various sensitization events, such as transfusion, pregnancy, or organ transplantation. However, the effects of a particular sensitization event on HLA alloimmunization have not been well studied in ..
  52. ncbi Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance
    Duska Dragun
    Clinic for Nephrology and Intensive Care Medicine Campus Virchow Klinikum and Center for Cardiovascular Research, Medical Faculty of the Charite, Berlin, Germany
    Curr Opin Organ Transplant 18:430-5. 2013
    ..on clinical studies testing clinical relevance of non-human leukocyte antigen (HLA) antigens in solid organ transplantation and provide an update on novel experimental findings...
  53. ncbi Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study
    C Ulrich
    Department of Dermatology, Skin Cancer Center, Charite University Hospital, 10117 Berlin, Germany
    Br J Dermatol 161:78-84. 2009
    ..Despite encouraging reports of protective effects of broad-spectrum sunscreens in immunocompetent patients, evidence for the prevention of NMSC in immunocompromised patients is still missing...
  54. ncbi Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy
    Andrea Willey
    Department of Dermatology, University of Minnesota, Minneapolis, Minnesota, USA
    Dermatol Surg 36:652-8. 2010
    ..The aim of this study was to evaluate the potential benefit of cyclic PDT in the prevention of new SCCs in SOTRs...
  55. ncbi Gene expression profiling of Epstein-Barr virus-positive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders
    Fiona E Craig
    Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Diagn Mol Pathol 16:158-68. 2007
    ..By contrast, EBV- PTLD lacked viral-associated changes suggesting that they are biologically distinct...
  56. ncbi The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline
    Nadine Shehata
    Department of Medicine, University of Toronto, Canadian Blood Services, St Michael s Hospital, 30 Bond Street, Toronto, Ontario, Canada
    Transfus Med Rev 24:S7-S27. 2010
    This guideline for the use of immunoglobulin (IG) for sensitized patients undergoing solid organ transplantation (SOT) is an initiative of the Canadian Blood Services and the National Advisory Committee on Blood and Blood Products of ..
  57. pmc Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era
    Andrew M Evens
    DO, MSc, Division of Hematology Oncology, 676 N St Clair S, Suite 850, Chicago, IL, 60611, USA
    J Clin Oncol 28:1038-46. 2010
    ..METHODS We examined the clinical features and outcomes among a large cohort of solid organ transplantation (SOT) -related patients with PTLD who were recently treated at four Chicago institutions (from January ..
  58. ncbi CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation
    Britta Maecker
    Department of Pediatric Hematology Oncology, Hannover Medical School, Hannover, Germany
    J Clin Oncol 25:4902-8. 2007
    To identify prognostic factors of survival in pediatric post-transplantation lymphoproliferative disorder (PTLD) after solid organ transplantation.
  59. ncbi Update in HIV infection in organ transplantation
    Paolo A Grossi
    Infectious Diseases Section, Department of Surgical and Morphological Sciences, University of Insubria, Varese, Italy
    Curr Opin Organ Transplant 17:586-93. 2012
    ..However, patients infected with HIV have traditionally been excluded from organ transplantation. Recent advances have had a significant impact on the potential transplant candidacy of these patients...
  60. ncbi Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis
    Heiner Zimmermann
    Department of Internal Medicine II, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany
    Cancer 118:4715-24. 2012
    ..In PTLD, however, such protocols are associated with considerable toxicity and mortality...
  61. ncbi Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients
    A Asberg
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway
    Am J Transplant 9:1205-13. 2009
    Though an important cause of morbidity and mortality in solid organ transplantation (SOT), the long-term outcomes of cytomegalovirus (CMV) disease treatment have not been well studied...
  62. ncbi The Seville expert workshop for progress in posttransplant lymphoproliferative disorders
    Denis Glotz
    Nephrology and Transplantation Service, Hopital Saint Louis, Paris, France
    Transplantation 94:784-93. 2012
    ..Finally, new classification criteria were outlined that may help facilitate standardized reporting and improve our understanding of PTLD...
  63. ncbi Polymorphonuclear leukocyte functions as predictive markers for infections after organ transplantation
    G Egger
    Institute of General and Experimental Pathology, Karl Franzens University, Graz, Austria
    Transpl Int 13:114-21. 2000
    Infectious complications are still a major cause of morbidity and mortality after organ transplantation, and early therapy would certainly reduce the risk associated with severe infections...
  64. ncbi Human cytomegalovirus end-organ disease is associated with high or low systemic viral load in preemptively treated solid-organ transplant recipients
    Giuseppe Gerna
    Laboratori Sperimentali di Ricerca, Area Trapiantologica, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    New Microbiol 35:279-87. 2012
    ....
  65. ncbi Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study
    Ann Marie Wennberg
    Department of Dermatology, Sahlgrenska University Hospital, Gothenburg University, Gothenburg, Sweden
    Transplantation 86:423-9. 2008
    ..Repeated field photodynamic therapy using topical methyl aminolevulinate (MAL) may have potential as a preventive treatment...
  66. ncbi Skin cancer in organ transplant recipients--where do we stand today?
    C Ulrich
    Department of Dermatology, Charite Universitatsmedizin, Berlin, Germany
    Am J Transplant 8:2192-8. 2008
    ..Presently, randomized prospective studies assess the burden of new skin tumors, as well as graft and patient survival, in patients with one or several NMSC after the introduction of mTOR (mammalian target of rapamycin) inhibitors...
  67. ncbi Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders
    V Leblond
    Departement d Hematologie, Hopital Pitie Salpetriere, Paris, France
    J Clin Oncol 19:772-8. 2001
    ....
  68. ncbi Biologics in organ transplantation
    Eugenia K Page
    Department of Surgery, Emory University Hospital, Atlanta, GA, USA
    Transpl Int 25:707-19. 2012
    ..Herein, we review the armamentarium of clinical and preclinical biologics used for organ transplantation--with the exception of belatacept--from depleting and IL-2R targeting induction agents to costimulation ..
  69. ncbi Impact of solid organ transplantation and immunosuppression on fever, leukocytosis, and physiologic response during bacterial and fungal infections
    R G Sawyer
    Charles O Strickler Transplant Center, Department of Surgery, University of Virginia, Charlottesville 22906 0005, USA
    Clin Transplant 13:260-5. 1999
    ..None of these differences appeared to affect overall mortality...
  70. ncbi Issues of adherence to immunosuppressant therapy after solid-organ transplantation
    Marie A Chisholm
    Department of Clinical and Administrative Sciences, University of Georgia College of Pharmacy and Department of Medicine, Medical College of Georgia, Augusta, Georgia, USA
    Drugs 62:567-75. 2002
    ..Because of possible adverse events, emphasis should be placed on increasing medication adherence in all transplant recipients...
  71. ncbi Rapamycin in combination with donor-specific CD4+CD25+Treg cells amplified in vitro might be realize the immune tolerance in clinical organ transplantation
    Chuntao Zhang
    Key Laboratory of Transplant Engineering and Immunology of Health Ministry of China, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan Province, PR China
    Cell Immunol 264:111-3. 2010
    ..tolerance without affecting the function of normal immune defense and immune surveillance in clinical organ transplantation. Large number of studies showed that both the establishment of donor-recipient chimerism and the ..
  72. ncbi B-cell immunotherapeutics: emerging roles in solid organ transplantation
    Stanley C Jordan
    Comprehensive Transplant Center, Kidney Transplant Program and Transplant Immunotherapy Program, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Curr Opin Organ Transplant 16:416-24. 2011
    ..These advances clearly have implications for patients receiving solid organ transplants, especially those who are ABO incompatible, sensitized to human leukocyte antigen (HLA) pretransplant, or develop anti-HLA antibodies posttransplant...
  73. ncbi Post-transplant lymphoproliferative disorder in children: recent outcomes and response to dual rituximab/low-dose chemotherapy combination
    Sushil Gupta
    Department of Pediatrics, University of Florida College of Medicine and Shands Children s Hospital, Gainesville, FL, USA
    Pediatr Transplant 14:896-902. 2010
    ..Other chemotherapy (n = 7, including all 4 T-cell PTLDs) had 57% CR, 0% recurrence and 14% mortality. Direct dual R/C combination therapy after failed RI is effective and offers another treatment option for B-cell PTLD...
  74. ncbi What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis
    D F Florescu
    Infectious Diseases Division, University of Nebraska Medical Center, Omaha, NE Transplant Surgery Division, University of Nebraska Medical Center, Omaha, NE
    Am J Transplant 13:2601-10. 2013
    Hypogammaglobulinemia has been described after solid organ transplantation and has been associated with increased risk of infections...
  75. ncbi Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma
    Qi Sun
    Department of Medicine, University of Alabama at Birmingham, 35294, USA
    Br J Haematol 118:799-808. 2002
    ..In conclusion, adoptive immunotherapy with allogeneic EBV-specific CTL is safe and may have efficacy in patients with high-risk or refractory EBV-related tumours...
  76. ncbi Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma
    Andrea Rinaldi
    Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland IOSI, Bellinzona, Switzerland
    Br J Haematol 149:569-77. 2010
    Post-transplant lymphoproliferative disorders (PTLD) are complications of solid organ transplantation associated with severe morbidity and mortality...
  77. ncbi Donor-derived hematopoietic cells in organ transplantation: a major step toward allograft tolerance?
    Gerard Rifle
    Department of Nephrology Intensive Care Transplantation, Hopital du Bocage, 2 Boulevard de Lattre de Tassigny, 21034 Dijon, France
    Transplantation 75:3S-7S. 2003
    ..cells (including stromal cells) to be used, the timing for infusion of donor cells in keeping with organ transplantation, the route of infusion (should it be intravenous, into the portal vein?), and the conditioning regimen...
  78. ncbi Heme oxygenase-1 system in organ transplantation
    Masamichi Katori
    Dumont UCLA Transplant Center, Division of Liver and Pancreas Transplantation, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Transplantation 74:905-12. 2002
    ..Thus, the HO-1 system serves as a novel therapeutic concept in organ transplantation.
  79. ncbi Tregs: application for solid-organ transplantation
    Ulrike Schliesser
    Institute of Medical Immunology, Charite University Medicine, Augustenburger Platz 1, Berlin, Germany
    Curr Opin Organ Transplant 17:34-41. 2012
    ..Here, we summarize the recent findings on human Treg subsets, their phenotype and in-vivo function...
  80. ncbi Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy
    Andrew M Evens
    Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Curr Oncol Rep 12:383-94. 2010
    ..Additionally, novel therapeutics, such as adoptive immunotherapy, should continue to be explored...
  81. pmc Immuno-intervention for the induction of transplantation tolerance through mixed chimerism
    David H Sachs
    Transplantation Biology Research Center, Massachusetts General Hospital, Building 149, 13th Street, Boston, MA 02129, United States
    Semin Immunol 23:165-73. 2011
    ....
  82. ncbi National conference to assess antibody-mediated rejection in solid organ transplantation
    Steven K Takemoto
    Dumont Transplant Program and Immunogenetics Center, UCLA School of Medicine, UCLA, Los Angeles, CA, USA
    Am J Transplant 4:1033-41. 2004
    ..Immunologic barriers once considered insurmountable are now consistently overcome to enable more patients to undergo organ transplantation.
  83. ncbi Epstein-Barr virus (EBV) genotypes among human immunodeficiency virus (HIV)-related B-cell lymphomas and B-cell post-transplant lymphoproliferative disorders (B-PTLD)--late-onset lymphomas, especially in the HIV setting, are associated with type-B-EBV
    Hazem A H Ibrahim
    Departments of Histopathology, Hammersmith Hospital and Imperial College, London, London, UK
    Eur J Haematol 85:227-30. 2010
    ..037) although there were no correlations with ethnicity, CD4 cell counts or plasma HIV viral load...
  84. ncbi Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion
    Efsevia Vakiani
    Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Hum Pathol 38:315-25. 2007
    ..Our findings provide validation of the current World Health Organization classification of PTLD and also suggest incorporation of FFH as the earliest recognizable precursor of PTLD...
  85. ncbi An update on donor-derived disease transmission in organ transplantation
    M G Ison
    Divisions of Infectious Diseases and Organ Transplantation, Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Am J Transplant 11:1123-30. 2011
    ..disease transmissions have highlighted the importance of this rare complication of solid organ transplantation. The epidemiology of donor-derived disease transmissions in the United States has been described through ..
  86. ncbi Post-transplant lymphoproliferative disorders following solid-organ transplantation
    Anne H Blaes
    University of Minnesota, Department of Hematology Oncology Transplantation, 420 Delaware Street S E, Minneapolis, MN 55455, USA
    Expert Rev Hematol 3:35-44. 2010
    ..lymphoproliferative disorder (PTLD) is an uncommon but serious complication following solid-organ transplantation. The incidence varies, depending on the type of organ transplanted, the degree of immunosuppression, the ..
  87. ncbi Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study
    Lawrence R Johnson
    Department of Pathology, Division of Hematopathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Am J Surg Pathol 30:1604-12. 2006
    ..The lack of a demonstrable correlation with survival may relate to the relatively small number of cases studied...
  88. ncbi The risk of microscopic colitis in solid-organ transplantation patients: a population-based study
    Gilaad G Kaplan
    Division of Gastroenterology, Gastrointestinal Research Group, Southern Alberta Transplant Program, Department of Pathology, University of Calgary, Calgary, Alberta, Canada
    Transplantation 85:48-54. 2008
    ..The objective of this work was to describe the risk of developing MC after solid-organ transplantation.
  89. ncbi Carbapenem-resistant Acinetobacter baumannii infections after organ transplantation
    P Reddy
    Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Transpl Infect Dis 12:87-93. 2010
    ..The current study suggests that SOT patients with CRAB suffer from prolonged hospitalization, infection with other MDR organisms, allograft dysfunction and loss, and high overall infection-related mortality...
  90. pmc Regenerative medicine as applied to solid organ transplantation: current status and future challenges
    Giuseppe Orlando
    Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
    Transpl Int 24:223-32. 2011
    ..This review describes recent advances in the engineering of several key tissues and organs...
  91. ncbi Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients: a prospective study of safety and immunogenicity
    Michelle Barton
    Division of Infectious Diseases, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario
    Pediatr Infect Dis J 28:688-92. 2009
    ..To determine the safety and immunogenicity of the conjugate pneumococcal vaccine (PCV7) in pediatric solid organ transplant recipients...
  92. ncbi Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation
    Fu Liang Ng
    Cellular and Molecular Medicine Renal Medicine and Cardiac and Vascular Sciences Analytical Unit, St George s, University of London, Cranmer Terrace, London, UK
    Expert Opin Pharmacother 8:2045-58. 2007
    Existing immunosuppressive therapies used for solid-organ transplantation have narrow therapeutic indices, whereby underdosing is associated with acute immunological rejection of the transplanted organ and overdosing is associated with ..
  93. ncbi Rare, unusual, and less common virus infections after organ transplantation
    Raymund R Razonable
    Division of Infectious Diseases, Department of Medicine, and William J von Leibig Transplant Center, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Curr Opin Organ Transplant 16:580-7. 2011
    ..The present article reviews the epidemiology, clinical presentation, prevention, and management of rare, unusual, and less common viruses that infect transplant recipients...
  94. pmc Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
    Paul D Griffiths
    Centre for Virology, UCL Medical School, London, UK
    Lancet 377:1256-63. 2011
    ..Values of viral load correlate with development of end-organ disease and are moderated by pre-existing natural immunity. Our aim was to determine whether vaccine-induced immunity could do likewise...
  95. ncbi Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants
    Nassim Kamar
    Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, Toulouse, France
    Gastroenterology 140:1481-9. 2011
    ....
  96. ncbi Repeat organ transplantation in the United States, 1996-2005
    J C Magee
    Scientific Registry of Transplant Recipients University of Michigan, Ann Arbor, Michigan, USA
    Am J Transplant 7:1424-33. 2007
    ..Even with careful case mix adjustments, the risk of graft failure following retransplantation is significantly higher than that observed for primary transplants...
  97. ncbi Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center
    Jason S Knight
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, USA
    J Clin Oncol 27:3354-62. 2009
    ..We studied the incidence, risk factors, treatment, and outcomes of post-transplantation lymphoproliferative disorder (PTLD) that occurred at the University of Michigan since 1964...
  98. ncbi Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials
    Elisabeth M Hodson
    National Health and Medical Research Council Centre for Clinical Research Excellence, Centre for Kidney Research, The Children s Hospital at Westmead, Sydney, Australia
    Lancet 365:2105-15. 2005
    ..We undertook a systematic review to investigate whether this approach affects risks of cytomegalovirus disease and death...
  99. ncbi Parasitic infections in organ transplantation
    Rashad S Barsoum
    Cairo University, Egypt
    Exp Clin Transplant 2:258-67. 2004
    ..It is recommended that transplant clinicians have a high index of suspicion of parasitic infections as an important transmission threat, as well as a potential cause of significant posttransplant morbidity...
  100. ncbi Chimerism in organ transplantation: conflicting experiments and clinical observations
    Anthony P Monaco
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Transplantation 75:13S-16S. 2003
    ..The presence of class II positive cells in the donor bone marrow inoculum is essential for tolerance induction in these models...
  101. ncbi The case for cytomegalovirus prophylaxis in solid organ transplantation
    David R Snydman
    Division of Geographic Medicine and Infectious Diseases, Department of Medicine, Tufts New England Medical Center and Tufts University School of Medicine, Boston, MA, USA
    Rev Med Virol 16:289-95. 2006
    ..Future trials with longer periods of prophylaxis are being undertaken...

Research Grants73

  1. Chymase-Mediated MMP Activation in Ishemia Reperfusion Injury
    LOUIS JOSEPH DELL'ITALIA; Fiscal Year: 2013
    ..consequences in various clinical settings such as thrombolytic therapy, cardiopulmonary bypass, organ transplantation, and acute percutaneous coronary angioplasty...
  2. Immune Regulation of Bone Homeostasis
    MERVYN NEALE WEITZMANN; Fiscal Year: 2012
    ..of numerous autoimmune and inflammatory diseases, and as anti-rejection agents in bone marrow and solid organ transplantation. The long term effects of these agents on the skeleton are unknown however, our preliminary studies ..
  3. Non-viral Genetic Modification of Antigen-presenting Cells in Allografts
    Wilson S Meng; Fiscal Year: 2011
    ..According to the Department of Health and Human Services, more than 25,000 patients undergo solid organ transplantation every year in the U.S. Approximately 100,000 patients are currently waiting for compatible transplants...
  4. DNA methylation of extracellular superoxide dismutase in pulmonary hypertension
    EVA NOZIK GRAYCK; Fiscal Year: 2012
    ..Aim 1 will utilize lung and pulmonary artery tissue and serum procured at the time of organ transplantation in patients with IPAH, disease-specific controls with PAH due to other causes, or patients without PAH to ..
  5. Inhibition of IkK to treat lethal Graft-vs.-Host Disease
    Patrick Flood; Fiscal Year: 2009
    ..As most new therapies for the treatment or prevention of GVHD have arisen from studies in solid organ transplantation, which does not involve inflammation-inducing conditioning therapy, we believe a new approach that focuses ..
  6. TLR4 Inhibition to Reduce Cerebral Ischemia Reperfusion Injury
    LORI ANN HOLLE; Fiscal Year: 2011
    ..Beyond cerebral IRI, any successful therapy to reduce IRI would have a profound impact on organ transplantation, myocardial damage due to CPB, and the natural history and treatment for MI and stroke...
  7. Human Beta-Defensin-1 in HSV-1 Innate Immunity
    LISA KATHLEEN RYAN; Fiscal Year: 2010
    ..persistent opportunistic infections in immunocompromised patients, such as those undergoing chemotherapy, organ transplantation, and those with immunodeficiencies and HIV...
  8. Optical Molecular Tomography for Regenerative Medicine
    Ge Wang; Fiscal Year: 2013
    ..b>Organ transplantation addresses some of these needs, but the scarcity of donors and the risk of immune suppression pose major ..
  9. Safety and PK Study in Hepatic Impairment Patients
    Weizhong Cai; Fiscal Year: 2010
    ..Given the lack of specific therapy, organ transplantation is the only clinically effective strategy...
  10. Pathogenesis of Oxidative Stress in Chagas Disease
    Nisha Jain Garg; Fiscal Year: 2013
    ..and increased population mobility, transmission through blood transfusion, congenital infection and organ transplantation has, in recent years, increased the human cases of Chagas in the US...
  11. HYPONATREMIA-INDUCED OSTEOPOROSIS
    Joseph G Verbalis; Fiscal Year: 2010
    ..in 44%, and chronic diseases of the gastrointestinal tract, chronic obstructive pulmonary disease, organ transplantation, autoimmune diseases, genetic diseases, and marrow-based and neoplastic disorders in 18% in aggregate...
  12. Novel Small Molecules For Acute Liver Failure
    Prakash Narayan; Fiscal Year: 2009
    ..Given the lack of specific therapy, organ transplantation is the only clinically effective strategy...
  13. Transplantation tolerance and immune function following mTOR inhibition.
    Jonathan D Powell; Fiscal Year: 2013
    ..It is hoped that the results of this study will allow safer application of this curative therapy to a greater number of patients and aid in improving tolerogenic therapy for autoimmunity and solid organ transplantation as well.
  14. Targeting Sirtuin-1 to enhance Foxp3+ regulatory T-cell function
    Ulf Beier; Fiscal Year: 2013
    ..Likewise, therapies for autoimmune diseases and organ transplantation face the challenge of achieving enough immunosuppression to prevent organ rejection or limit ..
  15. Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis
    Athan Kuliopulos; Fiscal Year: 2013
    ..b>Organ transplantation is a difficult, risky and costly procedure with scarce organ availability and increased risk of developing ..
  16. Antibody cytokine fusion proteins against Cryptococcus neoformans
    DAVID OWEN BEENHOUWER; Fiscal Year: 2012
    ..expansion of the number of persons with immunocompromise due to immuno- suppressive therapies for organ transplantation and rheumatic diseases as well as chemotherapy for cancer...
  17. Development of an Inhibitor of Toxoplasma gondii
    Richard D Wood; Fiscal Year: 2010
    ..who are at risk for toxoplasmosis include those infected with the parasite who also have cancer, undergo organ transplantation, autoimmune disease or those who receive immunosuppressive medicine for treatment of these and other ..
  18. Targeting Kinases that Phosphorylate the KSHV LANA Chromatin Binding Domain
    S Diane Hayward; Fiscal Year: 2013
    ..incidence of these cancers is increased in individuals who are immunocompromised such as those undergoing organ transplantation and those who are infected with human immunodeficiency virus 1 (HIV-1) and have AIDS...
  19. Endogenous regulators of inflammation in liver ischemia/reperfusion
    Allan Tsung; Fiscal Year: 2013
    ..I/R) is vital as it is commonly encountered clinically during elective liver surgical procedures, solid organ transplantation, trauma, and hypovolemic shock...
  20. Regulation of Nox Enzymes by Calcium and Novel Subunits
    J Lambeth; Fiscal Year: 2009
    ..disorders (ARDS, arthritis, atherosclerosis), and reperfusion injury (stroke, myocardial infarction, organ transplantation)...
  21. Regulation of Nox Enzymes by Calcium and Novel Subunits
    JOHN DAVID LAMBETH; Fiscal Year: 2013
    ..disorders (ARDS, arthritis, atherosclerosis), and reperfusion injury (stroke, myocardial infarction, organ transplantation)...
  22. Biomolecular Markers of Renal Allograft Status
    Thangamani Muthukumar; Fiscal Year: 2013
    ..quantitative PCR assays and participation as the PCR Core in NIH sponsored multi-center clinical trials of organ transplantation utilizing state-of-the art equipment for mRNA/miRNA profiling;(ii) the interdisciplinary renal transplant ..
  23. Cytokine Modulation of Heme Oxygenase-1 in Chronic Kidney Transplant Rejection
    Anupam Agarwal; Fiscal Year: 2010
    ..Despite significant progress in the field of organ transplantation, loss of transplanted kidneys remains a major problem, largel...
  24. Anti-CD47 mAb Therapy to Improve Kidney Transplantation
    PAMELA ANN TOY-MANNING; Fiscal Year: 2011
    DESCRIPTION (provided by applicant): Organ transplantation is one of the great success stories of modern medicine. However, the supply of suitable organs lags far behind the need and many patients die while waitlisted for organs...
  25. Kidney Donor Outcomes Cohort (KDOC) Study
    James R Rodrigue; Fiscal Year: 2013
    ..S. Department of Health and Human Services'Advisory Committee on Organ Transplantation. Reliable data on the surgical, medical, functional, psychological, and financial outcomes of living ..
  26. Genetics and visualization of innate host response to C. albicans infection in vi
    Robert T Wheeler; Fiscal Year: 2012
    ..carries a >30% attributable mortality and is associated with chemotherapy-induced neutropenia, organ transplantation, primary genetic defects such as chronic granulomatous disease, and medical procedures such as intravenous ..
  27. The effect of TLR4 inhibition on lung transplant ischemia-reperfusion injury
    PERRY ARTHUR GENOVA; Fiscal Year: 2010
    ..IRI is a significant problem in organ transplantation, because IRI is the major cause of primary graft failure and organ dysfunction after transplant...
  28. EMBRYONIC STEM CELLS INDUCE SPECIFIC GRAFT TOLERANCE
    Nicholas Zavazava; Fiscal Year: 2012
    Project Summary Organ transplantation is highly successful in the treatment of end-stage organ failure...
  29. ANTIGEN SPECIFIC T CELL TOLERANCE BY ANTI CD3 ANTIBODIES
    Claudio Anasetti; Fiscal Year: 2012
    ..Progress in the prevention of GVHD has the potential for advancing the fields of organ transplantation and therapy for autoimmune disorders...
  30. Access to Liver Transplantation for Patients with Primary Sclerosing Cholangitis
    David Seth Goldberg; Fiscal Year: 2011
    ..with primary sclerosing cholangitis are disadvantaged by the current liver allocation system, then this will form a foundation for which large-scale policy changes are considered to bring about a fairer system of organ transplantation.
  31. Delayed Tolerance Induction in Living Related Donor Renal Transplant Recipients
    Suzanne T Ildstad; Fiscal Year: 2012
    ..The findings from this study will directly translate to deceased donor organ transplantation. This is of high priority because most organ donors are deceased...
  32. Predicting the burden of renal disease among liver transplant recipients
    Pratima Sharma; Fiscal Year: 2013
    ..CMS) databases will provide me with a strong foundation and aid me in achieving my long term career goal to become an independent, interdisciplinary, clinical investigator and leader in the field of organ transplantation.
  33. Chagas Disease Confirmatory Assay
    Andrew Levin; Fiscal Year: 2009
    ..and Canada in recent years Chagas'disease has also been shown to be transmissible congenitally and by organ transplantation. These facts underscore the increasing attention to Chagas'disease as a public health and blood ..
  34. Genome Transplant Dynamics: non-invasive sequencing-based diagnosis of rejection
    HANNAH AUGUSTA contact VALANTINE; Fiscal Year: 2010
    ..genomic approach to the non-invasive, early diagnosis of rejection and graft dysfunction after solid organ transplantation, and addresses two targeted thematic areas: 1) Applying Genomics and Other High Throughput Technologies;2) ..
  35. Anti-CD47 mAb Therapy to Improve Kidney Transplantation
    PAMELA ANN TOY-MANNING; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Organ transplantation is a lifesaving option for those with end stage renal disease...
  36. Confirmatory Immunoblot Test for Chagas'Disease
    ANDREW E LEVIN; Fiscal Year: 2013
    ..Chagas'disease has also been shown to be transmissible congenitally and by organ transplantation. These facts underscore the increasing attention to Chagas'disease as a public health and blood ..
  37. The role of Nox2 in CNI-induced renal fibrosis
    Arjang Djamali; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Despite the tremendous success of solid organ transplantation in past 20 years, long-term kidney outcomes have been limited by chronic calcineurin inhibitor (CNI)-mediated fibrosis...
  38. Treatment of Transplant Reperfusion with CD47 antibody
    PAMELA ANN TOY-MANNING; Fiscal Year: 2013
    ..is developing a humanized anti-CD47 mAb for reducing ischemia-reperfusion injury (IRI) in organ transplantation. In spite of improvements in surgical technique, organ preservation and immunosuppression, IRI remains a ..
  39. Redox Regulation of RhoA and Modulation of Vascular Permeability
    Amir Aghajanian; Fiscal Year: 2012
    ..known as ischemia-reperfusion injury (IRI) often occurs as a consequence of infarction, shock, or organ transplantation. The effects of IRI can be localized, most often in the heart, lungs, intestines, or kidneys;or manifest ..
  40. TIM-3: Galectin-9: A Novel Regulatory Pathway of Alloimmune Activation
    Nader Najafian; Fiscal Year: 2011
    b>Organ transplantation is a life-saving procedure for patients with end-stage organ failure. Conventional immunosuppression leads to high morbidity and is unable to prevent chronic transplant dysfunction...
  41. MOCSLID-DCC
    Robert M Elashoff; Fiscal Year: 2012
    ..Mycophenolate mofetil (MMF), an immunosuppressive drug approved for organ transplantation, has been administered for up to 2 yrs to patients with SSc-ILD in several uncontrolled pilot studies...
  42. Therapeutic Antibodies for CMV
    WILLIAM ROBERT USINGER; Fiscal Year: 2013
    ..HCMV) is the major viral cause of birth defects and of medical complications associated with organ transplantation. Passive immunization using human immune globulin (HIG) has been shown to prevent disease...
  43. Interactions Between HLA Class I and Cytolytic Lymphocytes
    PETER R PARHAM; Fiscal Year: 2013
    ..of NK cells and their receptors should provide insights to the variabilityof the human NK response to infection, cancer, and the allogeneic cells encountered naturally in pregnancy and clinically in tissue and organ transplantation.
  44. T Cell Memory in Organ Transplantation
    Fadi G Lakkis; Fiscal Year: 2010
    ..Congenic markers will be used to track adoptively transferred CD8 memory T cells. Gene knockout mice and monoclonal antibodies will be used to examine the roles of chemokine receptors and adhesion molecules. ..
  45. Bioengineered siRNA/Nanoparticles to Prevent Human Transplant Rejection
    George Tellides; Fiscal Year: 2013
    ..propose to apply methods and insights of bioengineering and human immunology to a surgical therapy, namely organ transplantation. Our goal is to produce safe, efficient, selective and sustained knock down of immunostimulatory proteins ..
  46. Solid Organ Transplantation in HIV: Multi-Site Study
    Peter G Stock; Fiscal Year: 2010
    The primary aim of this study is to evaluate the safety and efficacy of solid organ transplantation in people with HIV disease by conducting a prospective, multi-center cohort of HIV-positive (+) patients who undergo kidney o liver ..
  47. Infection and Immunity K-12 Science Program: Exploring Knowns/Unknowns via VCRC/Q
    Marlys Hearst Witte; Fiscal Year: 2013
    ..wound/surgical infections;parasitic diseases from worms and insect vectors;1 and 2 immune disorders, organ transplantation;vaccines;and bioterrorism;3) provide K-12 teacher training and support through serial interactive ..
  48. Regulation of MHC Class II Genes
    Jeremy M Boss; Fiscal Year: 2013
    ..modulate MHC-II-based immune responsiveness for infectious disease, autoimmune disease, cancer, and organ transplantation. PUBLIC HEALTH RELEVANCE: Proper regulation of the MHC-II genes is central to a healthy and active immune ..
  49. Extended Storage of Tissues and Organs in Subzero Environments
    Martin L Yarmush; Fiscal Year: 2012
    ..crucial enabling technology for tissue and organ preservation, tissue and organ transport, and tissue and organ transplantation. The objective of this study is to extend the viable preservation time of hepatic tissues by sub-zero non- ..
  50. Protection against renal ischemic injury by short term dietary restriction
    James Mitchell; Fiscal Year: 2013
    ..Such clinical applications include ischemia reperfusion injury unavoidably incurred in a number of surgical procedures such as organ transplantation and cardiovascular surgery.
  51. The Impact of Tolerance in the Newborn on Lentiviral Infection
    Joseph M McCune; Fiscal Year: 2013
    ..g., autoimmune diseases) or conditions (e.g., organ transplantation) in which the induction of antigen-specific tolerance might be beneficial.
  52. Energy-based cold tolerance in genetically tractable eukaryotic systems
    Daniel H Shain; Fiscal Year: 2010
    ..e., days to weeks) offers great potential for treating human disease, and facilitating cell and organ transplantation. This research will investigate the acquired ability of diverse metazoan cells to resist cold temperature ..
  53. Function and regulation of TRPM7 Mg2+-inhibited cation channels
    JULIUSZ ASHOT KOZAK; Fiscal Year: 2010
    ..Conversely, immunosuppression is widely used in organ transplantation and autoimmune conditions...
  54. A Transdisciplinary Approach to Engage Specialty Investigators in Aging Research
    Kevin P High; Fiscal Year: 2013
    ..Aim 1, ASP will hold three research agenda setting meetings from 2012 through 2014 in the areas of solid organ transplantation in elderly patients, diabetes mellitus (DM) and cardiovascular (CV) complications in seniors, and wound ..
  55. Novel indication for myeloid progenitor use: Induction of tolerance
    Timothy C Fong; Fiscal Year: 2013
    ..State of the art techniques result in 10-year solid organ graft loss of up to 80% in cardiopulmonary organ transplantation, and re-transplantation is often not possible...
  56. MHC Class II Transactivator Function and Regulation
    JEREMY BOSS; Fiscal Year: 2009
    ..The results of these studies will ultimately identify targets for immune based therapies for the infectious disease, autoimmune disorders, and organ transplantation.
  57. Role of Endogenous Toll-Like Receptor Ligands in Allospecific T Cell Activation
    TODD VICTOR BRENNAN; Fiscal Year: 2013
    ..and to developing therapeutic approaches for mitigating these responses in order to improve outcomes in organ transplantation. PROJECT NARRATIVE: The overall goal of this project is to understand the mechanism by which injury to ..
  58. THE IMMUNOBIOLOGY OF CORNEAL ALLOGRAFTS
    Jerry Niederkorn; Fiscal Year: 2013
    ..No other form of solid organ transplantation can boast thi success rate under the same conditions...
  59. Ischemia-reperfusion injury in transplantation: novel cytoprotection strategies
    Reza Abdi; Fiscal Year: 2013
    ..The organ shortage has become a major obstacle hampering the success of organ transplantation worldwide, prompting clinicians to expand their criteria for the acceptance of marginal organs, which are ..
  60. IL-10 & PD-1 Modulation to Reduce CMV Disease Incidence in Solid Organ Recipients
    ABHIJIT PRAKASH LIMAYE; Fiscal Year: 2010
    ..are aimed to reduce the mortality and improve the clinical management of patients that have received solid organ transplantation (SOT)...
  61. CMV Entry-Specific Neutralizing Antibody in Primary Infection in Transplantation
    Margaret L Green; Fiscal Year: 2013
    ..increased mortality and increased risk of bacterial and fungal infections, and with graft failure in solid organ transplantation (SOT)...
  62. Proteogenomics for Organ Transplantation: Prediction, Diagnosis, Intervention
    Michael M Abecassis; Fiscal Year: 2013
    ..This study will develop blood biomarker-based metrics as a benchmark for adequate, long-term immunosuppression and detect non-immune renal injury before creatinine elevations are present. ..
  63. NF-kB Inhibition of Lung Ischemia Repurfusion Injury
    Patrick Flood; Fiscal Year: 2009
    ..IRI is also a major problem in organ transplantation, because IRI is the major cause of primary graft failure and organ dysfunction after transplant...
  64. Achieving Consensus on High Risk Donor to Improve Access to Organ Transplants
    Michael G Ison; Fiscal Year: 2011
    ..We therefore proposed a conference to bring together leaders in the field of solid organ transplantation to review research findings and evidence-based information...
  65. NOVEL CONCEPT FOR DEGRADATION OF ABSORBABLE POLYMERS
    Chih Chang Chu; Fiscal Year: 1990
    ..applications) or for patients with delayed wound healing due to diseases (AIDS, cancer, diabetes, organ transplantation)...
  66. PRECLINICAL BRIDGE TO HUMAN TRANSPLANT TOLERANCE
    Judith Thomas; Fiscal Year: 2000
    ..using a renal transplant model to serve as a preclinical bridge with direct relevance to clinical organ transplantation. Our preliminary studies in a novel posttransplant strategy (posttransplant rabbit antithymocyte globulin (..
  67. Treatment of Transplant Reperfusion with an Anti-CD47 Antibody
    PAMELA TOY MANNING; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Organ transplantation is one of the great success stories of modern medicine. However, the supply of suitable organs lags far behind the need and many patients die while waitlisted for organs...
  68. The Role of Bcl-2 in Ischemia-Reperfusion Injury
    Robert Winn; Fiscal Year: 2006
    ..reperfusion occurs in a variety of diseases including myocardial infarction, stroke, hemorrhagic shock and organ transplantation. We and others have shown that ischemia followed by reperfusion can result in a neutrophil (PMN)-induced ..
  69. PHOTOCHEMICAL DECONTAMINATION OF PLATELET CONCENTRATES
    Laurence Corash; Fiscal Year: 1993
    ..is currently estimated at 5-7 million units annually, and is expected to increase with expanded use of organ transplantation and intensive cancer chemotherapy...
  70. MOLECULAR STUDIES OF THE PROTEIN PHOSPHATASE CALCINEURIN
    WHYTE OWEN; Fiscal Year: 2002
    ..Calcineurin is the target of the immunosuppressant agents, cyclosporin A and FK506, important organ transplantation drugs that inhibit calcineurin phosphatase activity in the presence of the cytoplasmic proteins ..
  71. Iron Uptake and Mucormycosis Pathogenesis
    Ashraf Ibrahim; Fiscal Year: 2005
    ..infection that occurs in patients who are immunocompromised due to diabetic ketoacidosis, neutropenia, organ transplantation, and/or increased available serum iron...
  72. Role of SLc11a1 Gen in Warm Ischemia-Reperfusion Injury
    Samuel Wyllie; Fiscal Year: 2006
    ..and pharmacological interventions have improved the outcome of liver resections, hemorrhagic shock, and organ transplantation, injury, rejection and eventual organ failure due to Ischemia-reperfusion (I/R) injury continue to be ..
  73. INTERFERON RECEPTORS IN ORGAN TRANSPLANTATION
    Verna Gibbs; Fiscal Year: 1999
    ..The information generated from these studies may provide a rational basis for the development of agonists and antagonists which may be clinically useful in preventing acute graft rejection and chronic graft failure. ..